J&J buys Intra-Cellular in $14.6B deal, delving into central nervous system disorders
Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular. That represents a 39% premium to Intra-Cellular’s closing price of $94.87 on Friday. […]
J&J buys Intra-Cellular in $14.6B deal, delving into central nervous system disorders Read More »